Phase II trial of mitomycin-C in patients with small cell carcinoma of the lung after failure on combination chemotherapy.
Mitomycin-C was evaluated in a disease-oriented phase II trial in patients with small cell lung cancer who had failed prior conventional chemotherapy. The drug was given as a direct i.v. injection of 15 mg/m2 repeated every 6 weeks. No objective tumor response was observed among 15 evaluable patients. This precludes a 20% level of activity with 95% confidence. Leukopenia (60% of patients) and thrombocytopenia (20% of patients) were common-effects observed. One patient developed a microangiopathic hemolytic anemia after a total mitomycin-C dose of 42 mg. We conclude that mitomycin-C in this dose and schedule is an inactive agent in previously treated patients with small cell lung cancer.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D016685:Mitomycin